Jerrold J. Ellner

Jerrold J. Ellner

Auto-generated profile, based on publicly available information

Jerrold J. Ellner

Department of Medicine, Center for Emerging Pathogens, Rutgers New Jersey Medical School , Newark, New Jersey

Research Focus & Metrics

Academic Career Length

62Years (1965-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1995 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CWC Whalen
C Whalen
CJCharles Robert Horsburgh, Jr
Charles Robert Horsburgh, Jr
DHD Hom
D Hom
CLC Lahart
C Lahart
MSM Simberkoff
M Simberkoff
JEJ Ellner
J Ellner
To determine the effect of active tuberculosis on survival and the incidence of opportunistic infections in HIV-infected patients, we performed a retrospective cohort study at four U.S. medical centers to compare the survival and incidence rate of opportunistic infections in 106 HIV-infected patients with active tuberculosis (cases) with that of 106 HIV-infected patients without tuberculosis (control subjects) but with a similar level of immunosuppression (measured by the absolute CD4+ lymphocyte count) as the cases. Cases and control subjects were similar with regard to age, sex, race, previous opportunistic infection, and use of antiretroviral therapy, but they were more likely than control subjects to have a history of intravenous drug use (49 versus 19%). The mean CD4+ counts were similar for cases and control subjects (154 versus 153 cells/microliters, respectively). The incidence rate of new AIDS-defining opportunistic infections in cases was 4.0 infections per 100 person-months compared with 2.8 infections per 100 person-months in control subjects for an incidence rate ratio (RR) of 1.42 (95% confidence interval: 0.94-2.11). Cases also had a shorter overall survival than did controls subjects (p = 0.001). Active tuberculosis was associated with an increased risk for death (odds ratio = 2.17), even when controlling for age, intravenous drug use, previous opportunistic infection, baseline CD4+ count, and antiretroviral therapy. Although active tuberculosis may be an independent marker of advanced immunosuppression in HIV-infected patients, it may also act as a cofactor to accelerate the clinical course of HIV infection.

18 September 1997 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
CWChristopher C. Whalen
Christopher C. Whalen
JJJohn L. Johnson
John L. Johnson
AOAlphonse Okwera
Alphonse Okwera
DHDavid L. Hom
David L. Hom
RHRobin Huebner
Robin Huebner
VPVukosava Pekovic
Vukosava Pekovic
Infection with the human immunodeficiency virus (HIV) greatly increases the risk of reactivation tuberculosis. We evaluated the safety and efficacy of three preventive-therapy regimens in a setting where exposure to tuberculosis is common.

1 December 1999 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
CHChristina S. Hirsch
Christina S. Hirsch
ZTZahra Toossi
Zahra Toossi
COCatherine Othieno
Catherine Othieno
JJJohn L Johnson
John L Johnson
SSStephan K. Schwander
Stephan K. Schwander
JEJerrold J. Ellner
Jerrold J. Ellner
Immunological and clinical profiles were evaluated in 2 groups: human immunodeficiency virus (HIV)—uninfected and HIV-infected patients, with newly d

15 January 1994 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
CHC S Hirsch
C S Hirsch
JEJ J Ellner
J J Ellner
DRDavid Russell
David Russell
ERE A Rich
E A Rich
The relative phagocytosis and intracellular fate of Mycobacterium tuberculosis (MTB) (H37Ra) in human alveolar macrophages (AM) and their precursors blood monocytes (MN) was investigated. Uptake of MTB by MN and AM was confirmed by electron microscopy. At an infection ratio of 100:1 (MTB:target cell), the percentage of infected AM and the number of MTB per AM was > MN (p < 0.001, p < 0.0001, respectively). Uptake of MTB was increased by increasing concentrations of serum and decreased in the presence of heat-inactivated serum. Among complement receptors (CR) CR1, CR3, and CR4, the major CR mediating uptake of MTB by MN were CR1 and CR3, whereas for AM, CR4 was the major CR. When MN and AM were infected with MTB and cultured for up to 7 days, AM limited intracellular growth of MTB more effectively than MN as determined by a CFU assay. MTB stimulated production of TNF-alpha by mononuclear phagocytes and by AM > MN (p < 0.007). Pentoxifylline inhibited TNF-alpha production by mononuclear phagocytes and concurrently increased MTB growth (AM > MN). A polyclonal neutralizing antibody to TNF-alpha also increased MTB growth in AM. Thus, AM are more efficient in phagocytosis of MTB than MN, and uptake is mediated through CR4 to a greater extent than CR1 or CR3. The slowed replication of MTB in AM is associated with an increase in TNF-alpha production, and intracellular growth is promoted by pentoxifylline and neutralizing antibody to TNF-alpha. These data suggest that AM may play a prominent and efficient role in the primary defense of the lung in tuberculosis through CR-mediated uptake, predominantly CR4, and TNF-alpha-mediated killing of MTB.

1 January 1995 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ZTZ Toossi
Z Toossi
PGP Gogate
P Gogate
HSH Shiratsuchi
H Shiratsuchi
TYT Young
T Young
JEJ J Ellner
J J Ellner
The expression of TGF-beta, a molecule that affects both immune responsiveness and wound healing, was examined in blood monocytes and granulomatous lesions from patients with active pulmonary tuberculosis. The spontaneous release of TGF-beta was higher in culture supernatants of monocytes from patients as compared with those of healthy subjects by an ELISA (p < 0.0005). TGF-beta activity was also confirmed in a bioassay in supernatants from patients. Next, freshly isolated monocytes from patients with tuberculosis and matched subjects were examined for TGF-beta activity. Cytosmears of monocytes were stained with an Ab against TGF-beta 1 (anti-LC) or isotype-specific Ab by using an alkaline-phosphatase anti-alkaline phosphatase method. In contrast to monocytes from healthy individuals, 60 to 70% of monocytes from patients demonstrated cytoplasmic staining for TGF-beta (n = 3). Upon hypotonic lysis, monocytes from patients with tuberculosis contained immunoreactive TGF-beta (n = 3). By Northern blot analysis, monocytes from three of seven patients with tuberculosis had increased expression of TGF-beta mRNA as compared with concurrently examined monocytes from healthy subjects. Within the granulomas of lung sections from two patients with untreated tuberculosis, TGF-beta immunoreactivity was identified in the Langhan's giant cells mainly and to a lesser extent the epithelioid cells using anti-LC Ab and the peroxidase-anti-peroxidase technique. Thus, both blood monocytes and lung granuloma macrophages from patients with active tuberculosis express TGF-beta. Excess activity of this cytokine in blood monocytes may underlie the depressed T cell responses of patients with tuberculosis. Moreover, within the infected tissues excess TGF-beta activity may interfere with anti-mycobacterial mechanisms and effective granuloma formation.

1 September 1980 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PSPhilip J. Spagnuolo
Philip J. Spagnuolo
JEJerrold J. Ellner
Jerrold J. Ellner
AHAviv Hassid
Aviv Hassid
MDMichael J. Dunn
Michael J. Dunn
We examined the role of prostaglandins and thromboxanes as mediators of plasma-dependent increased polymorphonuclear leukocyte adhesiveness induced by Escherichia coli lipopolysaccharide. The cyclo-oxygenase inhibitors—indomethacin and d,l-6-chloro-α-methyl-carbozole-2-acetic acid (R020-5720)—reduced lipopolysaccharide-induced adherence of polymorphonuclear leukocytes by 74 and 62%, respectively. In addition, inhibitors of thromboxane synthetase—imidazole, 9,11-azoprosta-5,13-dienoic acid, and 1-benzylimidazole—suppressed the stimulation of adherence by 31, 66, and 83%, respectively. Exogenous prostaglandins E1, E2, and F2α did not increase polymorphonuclear leukocyte adherence, nor were they detected in significant quantities in supernates of polymorphonuclear leukocytes exposed to lipopolysaccharide. However, inhibitors of both cyclo-oxygenase and thromboxane synthetase reduced increases in adherence induced by arachidonic acid (10 μg/ml), suggesting that lipopolysaccharide-mediated increases in adherence were due to an arachidonic acid product other than prostaglandin E2 or F2α. 8,11,14-Eicosatrienoic acid, a precursor of monoenoic prostaglandins, did not enhance polymorphonuclear leukocyte adhesiveness. We next demonstrated lipopolysaccharide-stimulated generation, by polymorphonuclear leukocytes, of a labile, low molecular weight, dialyzable substance capable of enhancing the adherence of unstimulated leukocytes. In parallel experiments, a 10-fold increase in immunoreactive thromboxane B2 over basal levels was detected after exposure of leukocytes to lipopolysaccharide. The inhibition of lipopolysaccharide enhancement of adherence by specific rabbit antibodies to thromboxane B2 strongly supported a primary role for thromboxane A2 as the mediator of the observed increases in adherence. Lipopolysaccharide-stimulated purified platelets did not increase leukocyte adherence, whereas thrombin-stimulated platelets did increase adherence. These studies suggest that lipopolysaccharide stimulates polymorphonuclear leukocytes to produce thromboxane A2, which enhances their adhesiveness to nylon.